news
MSD acquisition to accelerate first-in-class COPD drug
The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease.
List view / Grid view
Verona Pharma
news
Trial to evaluate inhaled COVID-19 therapy finishes enrolment
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
news
Verona secures funding commitments to help progress RPL554
20 June 2016 | By Victoria White, Digital Content Producer
Verona Pharma has successfully secured funding commitments to raise gross proceeds of £44.7m through a conditional placing with new and existing investors...
news
Positive Phase IIa study data for RPL554 in COPD
10 May 2016 | By Victoria White, Digital Content Producer
RPL554 is a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule...
news
Verona Pharma announces positive headline data from RPL554 trial
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
news
Verona Pharma starts RPL554 Phase IIa combination study
14 October 2015 | By Victoria White
Verona Pharma has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for COPD...
